Breast Cancer | Unmet Need | HR-Positive/HER2-Negative | US/EU | 2021

Despite considerable progress in the treatment of HR-positive/HER2-negative metastatic breast cancer, the disease remains incurable. The approval and availability of the CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali and Piqray, and Eli Lilly’s Verzenio / Verzenios) have greatly expanded the treatment options for patients. A pressing need remains for later-line therapies following the development of hormone resistance. Key emerging agents under evaluation in this setting include: Immunomedics’ Trodelvy (sacituzumab govitecan); AstraZeneca’s capivasertib; Radius Health / Menarini’s elacestrant; Polyphor’s balixafortide; Odonate Therapeutics’ tesetaxel; and Athenex’s Oraxol. As competition intensifies in the metastatic HR-positive/HER2-negative breast cancer market, novel therapies will help to address the remaining unmet needs in this patient population.

QUESTIONS ANSWERED

• What are the most important factors that drive medical oncologists’ prescribing decisions for HR-positive/HER2-negative breast cancer?
• How do key current therapies, such as Pfizer’s Ibrance and Novartis’s Piqray, perform on key clinical attributes for this patient population?
• What are the prevailing areas of unmet need and hidden opportunities in this patient population?
• When considering new treatment options for metastatic HR-positive/HER2-negative breast cancer, what trade-offs are acceptable to surveyed medical oncologists between key clinical attributes and price per cycle?

DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by our experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in March 2021.

Key companies: Pfizer, Novartis, Eli Lilly, AstraZeneca.

Key drugs: Ibrance, Kisqali, Verzenio / Verzenios, Piqray, Afinitor, fulvestrant, letrozole, anastrozole, and exemestane.